Answers are grounded in this paper and cite their sources.
Examines cost-effective strategies for improving cryptococcal meningitis care in Malawi, indicating potential for better outcomes.
BACKGROUND: Cryptococcal meningitis (CM) causes 13%-20% of deaths among people living with HIV (PLHIV) globally. We examined the cost-effectiveness of improving access to CM diagnostics and treatment among PLHIV initiating HIV care with a positive serum cryptococcal antigen (CrAg) test in Malawi. METHODS: We used the CEPAC-I model to simulate (1) Current care (CM treatment if diagnosed with CM; otherwise preemptive fluconazole) and assessed 7 intervention strategies to expand care: (2) lumbar puncture (LP); (3) semi-quantitative serum CrAg (CrAgSQ) alone; or (4) CrAgSQ plus confirmatory LP for asymptomatic people with CrAg+; and (5) 98% access to liposomal amphotericin B/flucytosine/fluconazole (LAmB/5FC/Fluc) for diagnosed CM, as well as improving access to CM treatment with each diagnostic strategy (6, 7, 8). The simulated cohort has mean CD4 27/µL, age 37 years; 16% have symptomatic CM, 28% asymptomatic CM, and 56% asymptomatic cryptococcemia. Model outcomes include 1-year survival, quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs) assessed at 2 cost-effectiveness thresholds: US$150/QALY and US$600/QALY. RESULTS: Current care results in 70% 1-year survival, 10.67 QALYs, and costs US$2290/person. 98% access to LAmB/5FC/Fluc increases survival (+2.2%) and QALYs (+0.33 undiscounted QALYs) at lifetime costs of US$2320/person (ICER, US$140/QALY). CrAgSQ plus confirmatory LP for asymptomatic CrAg+ and 98% access to LAmB/5FC/Fluc results in +6.0% 1-year survival, +0.97 QALYs, +US$190/person (ICER, US$380/QALY). Results are sensitive to test characteristics and uptake. INTERPRETATION: Improving access to LAmB/5FC/Fluc and expanding diagnostics to improve detection of asymptomatic CM would improve clinical outcomes and be cost-effective in Malawi and similar settings.
No takes yet. Share an insight, caveat, or question.
Feser et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: